A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
|Articles|September 10, 2021
AJMC® in the Press, September 10, 2021
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
A piece by
Advertisement
Related to this article
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
Moderate coffee intake may lower cardiovascular risk, but energy drinks may harm the heart.
Wet work harms the skin barrier and microbiome as delgocitinib emerges.
Advertisement
Advertisement
Trending on AJMC
1
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
4
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
5